Terry J. Fry, M.D.

Terry J. Fry, M.D.
Investigator
Head, Hematologic Malignancies Section

Dr. Terry Fry heads the Hematologic Malignancies Section in the Pediatric Oncology Branch. His research is focused on the preclinical and clinical development of cell-based immunotherapy for pediatric leukemias. He is actively engaged in early phase clinical trials and national cooperative groups focused on improving outcomes in children and young adults with leukemia.

Areas of Expertise
1) pediatric leukemia, 2) immunotherapy, 3) adoptive cell therapy

Contact Info

Terry J. Fry, M.D.
Center for Cancer Research
National Cancer Institute
Building 10 - Hatfield CRC, Room 2-3942
Bethesda, MD 20892-1104
Ph: 301-402-0215
fryt@mail.nih.gov

Despite substantial improvements in outcome over the past three decades, leukemia remains a leading cause of cancer-related mortality in children.  Furthermore, even in patients cured by modern risk-adapted therapy, there are substantial long-term sequelae. Thus, newer treatments are needed, particularly those not based on standard cytotoxic agents.  The Hematologic Malignancies Section (HMS) conducts lab-based translational research focused on immunotherapeutic approaches for leukemia.  Clinical efforts in the treatment of leukemia occur within the Pediatric Oncology Branch (POB) clinical program where early phase clinical trials are conducted. The work currently taking place in the HMS and in the POB clinical program is focused on the use of cell-based immunotherapy for pediatric leukemia as well as more basic studies in leukemia biology.  In particular, the HMS is now heavily focused on the use of genetically modified T cells expressing chimeric antigen receptors (CAR) for the treatment of pediatric hematologic malignancies.   

Aim 1:  Translational development of chimeric antigen receptors for the treatment of pediatric leukemia

Using in vitro studies and xenograft models of pediatric acute lymphoblastic leukemia (ALL) in immune-deficient mice, the HMS performed preclinical optimization of a novel CD22-targeted CAR.  Dr. Fry leads the first-in-human clinical trial using this CAR in children and young adults with relapsed and refractory pre-B cell ALL.  The HMS also has other CAR constructs that target antigens expressed on pre-B cell ALL that will enter clinical trials in the near future.  Finally, the HMS is extending CAR therapy to other forms of pediatric leukemia, including acute myelogenous leukemia (AML) and T cell ALL.

Aim 2:  Elucidation of the biologic principles involved in the immunotherapeutic targeting of pediatric leukemia

The HMS utilizes a novel syngeneic murine model of CAR therapy for pre-B cell ALL that is being used to study in vivo biology of CAR therapy in an immunologically intact system.  Collectively, these studies have provided an opportunity to study immunotherapeutic resistance of ALL to CAR T cells. 

Scientific Focus Areas:
Cancer Biology, Clinical Research, Immunology
View Dr. Fry's PubMed Summary.

Selected Recent Publications

  1. Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, Qin H, Yang Y, Chien CD, Seif AE, Lei H, Song YK, Khan J, Lee DW, Mackall CL, Gardner RA, Jensen MC, Shern JF, Fry TJ.
    Nat Commun. 7: 12320, 2016. [ Journal Article ]
  2. Shah NN, Loeb DM, Khuu H, Stroncek D, Ariyo T, Raffeld M, Delbrook C, Mackall CL, Wayne AS, Fry TJ.
    Biol Blood Marrow Transplant. 22(12): 2149-2154, 2016. [ Journal Article ]
  3. Jacoby E1, Yang Y1, Qin H1, Chien CD1, Kochenderfer JN2, Fry TJ1.
    Blood. 127(10): 1361-70, 2016. [ Journal Article ]
  4. Qin H1, Cho M1, Haso W1, Zhang L1, Tasian SK2, Oo HZ3, Negri GL4, Lin Y5, Zou J5, Mallon BS6, Maude S2, Teachey DT2, Barrett DM2, Orentas RJ1, Daugaard M3, Sorensen PH4, Grupp SA2, Fry TJ1.
    Blood. 126(5): 629-39, 2015. [ Journal Article ]

Terry J. Fry received a B.A. from Colgate University in 1988 and an M.D. from Georgetown University in 1992. After completing a pediatric residency at Georgetown in 1995, he served as Chief Pediatric Resident. From 1996-1999, Dr. Fry undertook fellowship training in pediatric hematology and oncology at Johns Hopkins University. After postdoctoral training in the laboratory of Dr. Crystal Mackall, Dr. Fry established a research program focused on the immunology of stem cell transplantation as a platform for cancer immunotherapy.  Dr. Fry became Chief of the Division of Blood and Marrow Transplantation at Children's National Medical Center in 2007, a position he held until 2010 when he returned to the Pediatric Oncology Branch as Head of the Hematologic Malignancies Section. He is a member of multiple societies including the American Society of Hematology, the American Association of Immunology and the American Society of Blood and Marrow Transplantation and was elected into the American Society of Clinical Investigation. He also serves in leadership positions in the Oncology Strategy Group in the Pediatric Blood and Marrow Transplant Consortium and the Cellular Therapy Committee in the Children's Oncology Group.

Name Position
Christopher Daniel Chien Ph.D. Biologist
Kazusa Ishii M.D. Clinical Fellow
Mark Kohler M.D. Clinical Fellow
Haiying Qin M.S. Biologist
Sneha Ramakrishna M.D. Clinical Fellow
Vicki Richmond Program Assistant
Lila Yang B.S. Postbaccalaureate Fellow (CRTA)
Yinmeng Amy Yang Ph.D. Postdoctoral Fellow (CRTA)
Bonnie Yates R.N. Nurse Specialist